Alzheimer neurofibrillary degeneration: significance, etiopathogenesis, therapeutics and prevention. - sprookjes - yvandenbroek - TriplyDB

Alzheimer neurofibrillary degeneration: significance, etiopathogenesis, therapeutics and prevention.

Alzheimer neurofibrillary degeneration: significance, etiopathogenesis, therapeutics and prevention.

http://www.wikidata.org/entity/Q35114797

about

Recent developments of protein kinase inhibitors as potential AD therapeutics Drug Development in Alzheimer's Disease: The Contribution of PET and SPECT Effect of the inhaled anesthetics isoflurane, sevoflurane and desflurane on the neuropathogenesis of Alzheimer's disease (review)Tau-targeted treatment strategies in Alzheimer's disease The flavonoid quercetin ameliorates Alzheimer's disease pathology and protects cognitive and emotional function in aged triple transgenic Alzheimer's disease model mice The preclinical phase of the pathological process underlying sporadic Alzheimer's disease A novel blood-brain barrier co-culture system for drug targeting of Alzheimer's disease: establishment by using acitretin as a model drug Animal models for Alzheimer's disease and frontotemporal dementia: a perspective Brains with medial temporal lobe neurofibrillary tangles but no neuritic amyloid plaques are a diagnostic dilemma but may have pathogenetic aspects distinct from Alzheimer disease.Involvment of cytosolic and mitochondrial GSK-3beta in mitochondrial dysfunction and neuronal cell death of MPTP/MPP-treated neurons Quantitative structural MRI for early detection of Alzheimer's disease.The efficacy of Epigallocatechin-3-gallate (green tea) in the treatment of Alzheimer's disease: an overview of pre-clinical studies and translational perspectives in clinical practice.Dexibuprofen prevents neurodegeneration and cognitive decline in APPswe/PS1dE9 through multiple signaling pathways.CpG and Non-CpG Methylation in Epigenetic Gene Regulation and Brain Function Potential therapeutic strategies for Alzheimer's disease targeting or beyond β-amyloid: insights from clinical trials mNos2 deletion and human NOS2 replacement in Alzheimer disease models Structure and pathology of tau protein in Alzheimer disease.Basis for MAP4 dephosphorylation-related microtubule network densification in pressure overload cardiac hypertrophy.SUMOylation at K340 inhibits tau degradation through deregulating its phosphorylation and ubiquitination.Tau in Alzheimer disease and related tauopathies.Drug discovery from Chinese medicine against neurodegeneration in Alzheimer's and vascular dementia Leucine-rich α-2-glycoprotein is a marker for idiopathic normal pressure hydrocephalus.Amyloid and tau pathology of familial Alzheimer's disease APP/PS1 mouse model in a senescence phenotype background (SAMP8).Morin attenuates tau hyperphosphorylation by inhibiting GSK3β.The toxicity of tau in Alzheimer disease: turnover, targets and potential therapeutics Neurofibrillary tangle pathology and Braak staging in chronic epilepsy in relation to traumatic brain injury and hippocampal sclerosis: a post-mortem study CLOCK Genes and Circadian Rhythmicity in Alzheimer Disease.Minocycline corrects early, pre-plaque neuroinflammation and inhibits BACE-1 in a transgenic model of Alzheimer's disease-like amyloid pathology.Activation of protein phosphatase 2B and hyperphosphorylation of Tau in Alzheimer's disease.Neurochemical biomarkers in Alzheimer's disease and related disorders.Precortical Phase of Alzheimer's Disease (AD)-Related Tau Cytoskeletal Pathology Anesthesia and tau pathology.Biomarkers for early diagnosis of Alzheimer disease: 'ALZheimer ASsociated gene'--a new blood biomarker?Pharmacological Treatment of Alzheimer's Disease: Is it Progressing Adequately?Crosstalk between Cdk5 and GSK3beta: Implications for Alzheimer's Disease Cytosolic abnormally hyperphosphorylated tau but not paired helical filaments sequester normal MAPs and inhibit microtubule assembly Pharmacotherapeutic targets in Alzheimer's disease The marine natural-derived inhibitors of glycogen synthase kinase-3beta phenylmethylene hydantoins: In vitro and in vivo activities and pharmacophore modeling.Rationale for peptide and DNA based epitope vaccines for Alzheimer's disease immunotherapy.Novel strategies for the prevention of dementia from Alzheimer's disease.

P2860

Q21129481-4A7AFA56-BC25-40B2-90FF-E89D89C341F2 Q26749755-7F9773FC-E6D7-4D50-8F49-AC72ED5AD958 Q27001244-22B5F2BD-056A-46AA-A667-CB5517444A08 Q27023429-1FDABB77-751A-46CA-81D7-5A88F0EACC11 Q27305145-0744C799-1761-4B9C-9580-6CAC26113DC9 Q28083428-CB2E5CA3-9B16-4546-981C-3D8FC35E4C4D Q28540639-26D26A23-DC31-4029-8351-2A13D40EAC9C Q28749702-4EBC3B4D-5C0A-46A3-BE76-1F6D8F17280D Q30378181-8FB83B92-5485-4B9B-8FD8-650D66484C94 Q33442821-48A9AC46-B604-430C-81B1-0815FDDD7FA5 Q33729033-8402026A-1C02-4FA4-961F-342C6BF6150F Q33814399-6A87DB79-C4FC-4808-A54E-BE40765E4463 Q33825472-5DBD8685-4F72-42C4-A2C2-A779599927B1 Q33836737-56009499-7360-455F-A51C-EC9891D04333 Q34014237-4D99043A-916D-467A-99A8-508E149BAD01 Q34041402-26579DC9-D87B-4DD7-86D7-867C306A6FB3 Q34280787-268F491F-3F57-4AE9-999F-3435BF908CFB Q34352102-D83B59CA-6FFF-4689-B288-F1235E30940E Q34581013-00C10DB4-439D-49DB-93D6-D42FD86A8766 Q34953869-2D709817-79B7-4785-9AEB-843CB7C68E1D Q34989295-5B5B03CA-1FDF-432C-AA53-E6D342E7CE75 Q34995705-536B028C-710E-44F8-ADC1-FEFE5F0F88E7 Q35058977-42BD07B0-71DE-4C5B-A1DA-792678A7D067 Q35196301-59464D26-0755-457B-B884-F36B12733DF1 Q35216140-05E2042C-C67C-4632-9BC3-4987EA3CA8DD Q35275393-3C9F4C1C-5DD4-439A-8EE5-C347DD06AD21 Q35418059-A9926022-87CA-4178-B68D-00ADF0BCB11A Q35959633-F2B492AD-2671-4BCE-9EE6-3D9D37EC8261 Q36039037-E31E4A65-EE7F-468F-8EC3-9EEEFAC50EE6 Q36366891-CFBE45AA-6A2B-4002-8848-63E0D3834D1D Q36484091-FE986FE7-84E9-4C41-BEC1-EC37FFA1DD4A Q37089765-69998138-2347-4A29-A522-80603EAC4CE5 Q37118083-41AA3671-DA54-40A1-8391-4FBCADB2E0CF Q37198579-48BCD70C-4CC5-4F69-A426-BD44DCF06472 Q37223230-179ACCBF-20ED-4112-BEA5-7F6FC8E4C4D5 Q37238256-BBAAD3F6-D59C-4E66-BCD9-97C96137B842 Q37295067-F9B5DB46-F65D-4D0D-88C6-BB186CA637A6 Q37345648-19AC1A6F-CCBC-4ECA-9623-E37C948E19EB Q37438261-37A3F5E9-465D-43C8-84E0-09D9BB633A30 Q37544750-B6373D0D-ADA1-42C3-887D-FF1AA83A2E27

P2860

Alzheimer neurofibrillary degeneration: significance, etiopathogenesis, therapeutics and prevention.

http://www.wikidata.org/entity/Q35114797

description

2007 nî lūn-bûn

@nan

2007 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

Alzheimer neurofibrillary dege ...... , therapeutics and prevention.

@ast

Alzheimer neurofibrillary dege ...... , therapeutics and prevention.

@en

type

label

Alzheimer neurofibrillary dege ...... , therapeutics and prevention.

@ast

Alzheimer neurofibrillary dege ...... , therapeutics and prevention.

@en

prefLabel

Alzheimer neurofibrillary dege ...... , therapeutics and prevention.

@ast

Alzheimer neurofibrillary dege ...... , therapeutics and prevention.

@en

P1433

Q35114797-89857665-C1E6-4273-9A79-BA15DE24D15C

P1476

Q35114797-1590803A-9C0D-41FD-943C-DE8411D69D3C

P2093

Q35114797-49106449-A4A6-463B-A02C-BC64DAB9BB6A

Q35114797-B2ABDAF6-7E18-434A-8060-062AACE3BB77

P2860

Q35114797-004A766B-B152-4CEB-8377-9E8D60F49E4C

Q35114797-0184F3BE-B9D6-4DC2-BDCE-22CC7A4B2A41

Q35114797-034A26EE-5B0D-4E85-B080-906933FB6192

Q35114797-055E4BC7-9C2F-4B83-A47E-806A91741296

Q35114797-08FD6CEF-9E17-4CFD-93C5-4B1964A37A78

Q35114797-0F87DAF3-F940-4D72-B85F-BE03FB1BF16C

Q35114797-10B57C73-6BA0-4FEF-BF88-C35F9FF78C77

Q35114797-14E32A1C-5DAF-4749-A6E4-5780153DB15B

Q35114797-1518222C-A3C7-4A08-83A7-361ECB550180

Q35114797-17BD71E8-A684-41E7-83F8-F74D73B2CB5F

P304

Q35114797-88BA10F8-076F-49AC-B472-054D092EDD8A

P31

Q35114797-32BF6646-31FF-4A25-B742-58A7AE856C12

Q35114797-FD615D90-A85D-45D0-BBA2-14BF4DE13AA9

P356

Q35114797-682FCF6D-B46B-4C35-B9BC-39334C2ADD79

P433

Q35114797-C4058860-921F-45AA-9CC3-9B357926D802

P478

Q35114797-C7F792F0-EC8E-4127-B812-3CB3035610DF

P577

Q35114797-1B3F2373-1810-400E-9C17-A7E50436F98D

P5875

Q35114797-ABA29427-5848-4676-B3A7-D29C8DF46481

P698

Q35114797-9921B687-9C76-4C9A-8DC5-8ED169634DEF

P921

Q35114797-462906BF-EEE6-40DD-AD62-09D30CC26845

Q35114797-48F2FB35-09F7-49B5-9BDE-3BCD693DB3A1

Q35114797-B272F5EB-F697-45D4-8EB4-B7C69C0F32BA

Q35114797-BE75EFED-3C19-4323-B40D-E613B93DD1CE

P932

Q35114797-BF4B6C7A-BF9A-4C5E-A1D7-4D6122365FAD

P356

J.1582-4934.2008.00225.X

P1433

Journal of Cellular and Molecular Medicine

P1476

Alzheimer neurofibrillary dege ...... , therapeutics and prevention.

@en

P2093

I Grundke-Iqbal

http://www.w3.org/2001/XMLSchema#string

K Iqbal

http://www.w3.org/2001/XMLSchema#string

P2860

A protein factor essential for microtubule assembly

FAD mutants unable to increase neurotoxic Aβ 42 suggest that mutation effects on neurodegeneration may be independent of effects on Aβ

Tau pathology in Alzheimer disease and other tauopathies

The myeloid leukemia-associated protein SET is a potent inhibitor of protein phosphatase 2A

Caspase cleavage of tau: linking amyloid and neurofibrillary tangles in Alzheimer's disease

Microtubule-associated protein/microtubule affinity-regulating kinase (p110mark). A novel protein kinase that regulates tau-microtubule interactions and dynamic instability by phosphorylation at the Alzheimer-specific site serine 262

MARK, a novel family of protein kinases that phosphorylate microtubule-associated proteins and trigger microtubule disruption

Amyloid plaque core protein in Alzheimer disease and Down syndrome

Hyperphosphorylation induces self-assembly of tau into tangles of paired helical filaments/straight filaments

Can, a putative oncogene associated with myeloid leukemogenesis, may be activated by fusion of its 3' half to different genes: characterization of the set gene

P304

38-55

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1582-4934.2008.00225.X

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P577

2007-01-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5658009

http://www.w3.org/2001/XMLSchema#string

P698

18194444

http://www.w3.org/2001/XMLSchema#string

P921

Alzheimer's disease

nerve degeneration

P932

3139457

http://www.w3.org/2001/XMLSchema#string